Danny Isawi
Family Medicine · Terre Haute, INNPI 1639585136
Payments from drug & device makers
Across 241 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$747
- GSK$381
- Novo Nordisk$323
- E.r. Squibb & Sons, L.L.C.$269
- Amgen$244
- Johnson & Johnson$171
- plus $2K from 33 others
What the payments were for
- Food & beverage$3,951100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 48 | $747 |
| GSK | 19 | $381 |
| Novo Nordisk | 20 | $323 |
| E.r. Squibb & Sons, L.L.C. | 18 | $269 |
| Amgen | 15 | $244 |
| Johnson & Johnson | 11 | $171 |
| Boehringer Ingelheim | 10 | $160 |
| Abiomed | 7 | $158 |
| AstraZeneca | 10 | $155 |
| AbbVie | 7 | $127 |
| Dexcom, Inc. | 6 | $97 |
| Abbott | 6 | $95 |
| Bayer | 6 | $91 |
| Exact Sciences | 4 | $88 |
| Kowa Pharmaceuticals America, Inc. | 6 | $86 |
| Lilly USA, LLC | 6 | $79 |
| Novartis | 5 | $76 |
| Corcept Therapeutics | 2 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $58 |
| Astellas Pharma US Inc | 3 | $44 |
| Sanofi Pasteur Inc. | 2 | $38 |
| Merck | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| Sumitomo Pharma America, Inc. | 2 | $28 |
| Lundbeck LLC | 1 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Ironwood Pharmaceuticals, Inc | 2 | $25 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Nevro Corp. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Ascensia Diabetes Care US Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$3,951 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 182 | $173,863 |
| OzempicSemaglutide | 99 | $110,002 |
| XareltoRivaroxaban | 63 | $71,505 |
| TrulicityDulaglutide | 43 | $53,021 |
| JardianceEmpagliflozin | 40 | $42,535 |
| RybelsusSemaglutide | 24 | $38,726 |
| JanuviaSitagliptin Phosphate | 34 | $38,649 |
| FarxigaDapagliflozin Propanediol | 36 | $34,496 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 41 | $27,295 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 45 | $23,751 |
| MounjaroTirzepatide | 21 | $20,892 |
| TradjentaLinagliptin | 12 | $18,368 |
| Tresiba Flextouch U-100Insulin Degludec | 55 | $17,619 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $14,194 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 23 | $13,776 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $747 | $176,688197 claims |
| Novo NordiskOzempic, Rybelsus | $323 | $148,728123 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $79 | $73,91364 claims |
| Johnson & JohnsonXarelto | $171 | $71,50563 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $381 | $64,883133 claims |
| Boehringer IngelheimJardiance, Tradjenta | $160 | $60,90352 claims |
| MerckJanuvia, Janumet Xr | $29 | $52,42657 claims |
| AstraZenecaFarxiga, Brilinta | $155 | $42,70148 claims |
| AbbVieLinzess | $127 | $8,90613 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $7,43311 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $28 | $6,57612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Terre Haute
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.